MedTrace Logo

Clinical Utility Trial for the SomaLogic CVD-T2D Test

NCT05237271 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2022-08-22

No results posted yet for this study

Summary

QURE will use its CPV technology in a randomized controlled trial to measure how SomaLogic's diagnostic test (the Cardiovascular Disease in Type 2 Diabetes) changes clinical practice and improves patient outcomes.

Conditions

Interventions

OTHER

Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)

Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.

OTHER

Educational Materials on the CVD-T2D and Bundled Metabolic Panel

Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.

Sponsors & Collaborators

  • SomaLogic, Inc.

    collaborator INDUSTRY

  • Qure Healthcare, LLC

    lead INDUSTRY

Principal Investigators

  • John W Peabody, MD, PhD · QURE Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2022-08-15
Completion
2022-08-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05237271 on ClinicalTrials.gov